Once yearly cell-based therapy for sustained and dose-tunable delivery of monoclonal antibodies. (PubMed, Sci Adv) - Oct 3, 2026 - "Screening chemically modified alginate biomaterials in immunocompetent mice identified a lead immunomodulatory alginate formulation that sustains stable serum titers of the HIV-neutralizing mAb 3BNC117 for 1 year...The platform's versatility was demonstrated by the production of 13 diverse mAbs from an allogeneic cell chassis, with sustained in vivo delivery of a subset including ipilimumab, pembrolizumab, adalimumab, and PGT121...These results demonstrate a clinically translatable platform that offers a practical strategy to replace frequent injections with single-administration therapy. A cell-based delivery platform within an antifibrotic minimally invasive device enables year-long mAb delivery."
Journal • Fibrosis • Human Immunodeficiency Virus • Immunology • Infectious Disease
|
|
Amir Ardeshir; Anthony E Davis; Chancellor Smith; Christy L Lavine; Cody Fell; Danna Murungi; Erin M Haupt; Imaan Mohandessi; Jonathon DeBonis; Michael R Diehl; Michael S Seaman; Michael T Guinn; Nathan Brown; Oleg Igoshin; Omid Veiseh; Patrick Bednarz; Ravi K Ghanta; Samuel I Cuevas; Shalini Pandey; Yeonju Kim; Zeshi Wang
|